R‑Zero Raises $105 Million Series C

-Zero today announced it has closed a $105 mil­lion Series C to con­tin­ue scal­ing the adop­tion of its UV‑C tech­nol­o­gy to address a grow­ing health cri­sis: dis­in­fect­ing the indoor air we breathe. Investors include BMO Finan­cial Group, Qual­comm Ven­tures, and Upfront Ven­tures, and exist­ing investors DBL Part­ners, World Inno­va­tion Lab, Mayo Clin­ic, Bedrock Cap­i­tal, SOSV, and John Doerr.

The round brings R‑Zero’s total amount of cap­i­tal raised to more than $170 mil­lion. Funds from the Series C will help the com­pa­ny scale deploy­ments of its dis­in­fec­tion and risk mod­el­ing tech­nol­o­gy to meet grow­ing demand across pub­lic and pri­vate sec­tors, includ­ing K‑12 schools, col­lege cam­pus­es, cor­po­rate cam­pus­es, hos­pi­tals, senior care com­mu­ni­ties, parks and recre­ation, and oth­er gov­ern­ment facil­i­ties. R‑Zero’s dis­in­fec­tion tech­nol­o­gy has a pos­i­tive impact on peo­ple, by neu­tral­iz­ing 99.99% of harm­ful microor­gan­isms that live in the indoor air we breathe, and on the plan­et through low­er ener­gy con­sump­tion and waste production.

To read the full arti­cle, please vis­it: tech­buzz